Milliman Irix Risk Score 2.2 Whitepaper
Munich Re assessed the effectiveness of Milliman Irix® Risk Score 2.2 in stratifying the mortality for the U.S. insurance applicant population.
Munich Re assessed the effectiveness of Milliman Irix® Risk Score 2.2 in stratifying the mortality for the U.S. insurance applicant population.
Munich Re assessed the Milliman Rx Risk Score, a predictive modeling tool developed and owned by Milliman that assesses mortality risk using an individual’s prescription drug information. Insurers considering prescription- drug-based scores should begin with a retrospective validation study on their own experience data.